¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gene genetics"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene expression
    À¯ÀüÀÚ¹ßÇö
  • gene family
    À¯ÀüÀÚ±º
  • gene frequency
    À¯ÀüÀÚºóµµ
  • gene imbalance
    À¯ÀüÀÚºÒÆòÇü
  • gene map
    À¯ÀüÀÚÁöµµ
  • gene mapping
    À¯ÀüÀÚÀ§Ä¡ÁöÁ¤, À¯ÀüÀÚÁöµµÀÛ¼º
  • gene pool
    À¯ÀüÀÚÇ®
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ
  • gene redundancy
    À¯ÀüÀÚÁߺ¹
  • gene regulation
    À¯ÀüÀÚÁ¶Àý
  • gene replacement
    À¯ÀüÀÚ±³È¯
  • gene segment
    À¯ÀüÀÚÁ¶°¢
  • gene splicing
    À¯ÀüÀÚ½ºÇöóÀ̽Ì, À¯ÀüÀÚÀß¶óÀÌÀ½
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
  • gene transfection
    1. À¯ÀüÀÚÀü´Þ°¨¿° 2. À¯ÀüÀÚÇÙ³»ÁÖÀÔ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene redundancy
    À¯ÀüÀÚ¿©À¯
  • gene regulation
    À¯ÀüÀÚÁ¶Àý
  • gene replacement
    À¯ÀüÀÚ±³È¯
  • gene segment
    À¯ÀüÀÚÁ¶°¢
  • gene transfection
    À¯ÀüÀÚÀü´Þ°¨¿°
  • gene transfer
    À¯ÀüÀÚÀü´Þ
  • gene translocation
    À¯ÀüÀÚÀüÀ§
  • gonosomal gene
    ¼º¿°»öüÀ¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕÇ׿øÀ¯ÀüÀÚ
  • hox gene
    Ȥ½ºÀ¯ÀüÀÚ
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • major histocompatibility gene
    ÁÖÁ¶Á÷ÀûÇÕ¼ºÀ¯ÀüÀÚ
  • marker gene
    Ç¥ÁöÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene conversion
    À¯ÀüÀÚº¯È¯.
  • gene conversion
    À¯ÀüÀÚº¯È¯(ܨüµ).
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ.
  • gene defect
    À¯ÀüÀÚ°á¼Õ<--°á¿©>
  • gene deletion
    À¯ÀüÀÚ°á½Ç<--»èÁ¦
  • gene, mutator
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
  • gene, operator
    ÀÛµ¿À¯ÀüÀÚ
  • gene, regulatory
    Á¶ÀýÀ¯ÀüÀÚ
  • gene, repressor
    ¾ïÁ¦À¯ÀüÀÚ
  • gene, structural
    ±¸Á¶À¯ÀüÀÚ
  • gene, suppressor
    ¹ßÇö¾ïÁ¦À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕ¼º À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕÀ¯ÀüÀÚ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • calcitonin-gene related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • complementary gene
    º¸Á·À¯ÀüÀÚ(ÜÍðëë¶îîí­), º¸Ã¼À¯ÀüÀÚ.
  • contiguous gene syndrome
    Á¢Ã˼º À¯ÀüÀÚ ÁõÈıº(ïÈõºàõë¶îîí­ñøý¦ÏØ)
  • contiguous gene syndrome
    ÀÎÁ¢ À¯ÀüÀÚ ÁõÈıº
  • control gene
    Á¦¾îÀ¯ÀüÀÚ(ð¤åÙë¶îîí­).
  • covering gene
    ÇǺ¹À¯ÀüÀÚ(¡­ë¶îîí­).
  • dcc gene
    DCC À¯ÀüÀÚ(¡­ë¶îîí­)
  • determinant gene
    °áÁ¤À¯ÀüÀÚ(̽ïÒë¶îîí­).
  • dominant autosomal gene
    ¿ì¼ºº¸Åë¿°»öüÀ¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ(¡­ë¶îîí­).
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ(éÐàõë¶îîí­).
  • dq3.2 gene
    DQ3.2 À¯ÀüÀÚ(¡­ë¶îîí­)
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ.
  • exaggeration gene
    °­Á¶À¯ÀüÀÚ(¡­ë¶îîí­).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gene fusion
    À¯ÀüÀÚ À¶ÇÕ(ë¶îîí­ë×ùê)
  • gene hypothesis
    À¯ÀüÀÚ ¼³(ë¶îîí­àã)
  • gene insertion
    À¯ÀüÀÚ »ðÀÔ(ë¶îîí­ßºìý)
  • gene library
    À¯ÀüÀÚ(ë¶îîí­) ¶óÀ̺귯¸®
  • gene linkage
    À¯ÀüÀÚ ¿¬°ü(ë¶îîí­Ö¤Î¼)
  • gene locus
    À¯ÀüÀÚ ºÎÀ§(ë¶îîí­Ý»êÈ)
  • gene mapping
    À¯ÀüÀÚ ÀÛµµ(ë¶îîí­íÂÓñ)
  • gene pair
    À¯ÀüÀÚ ½Ö(ë¶îîí­äª)
  • gene pool
    À¯ÀüÀÚ(ë¶îîí­) Ç®
  • gene product
    À¯ÀüÀÚ(ë¶îîí­) »ê¹°
  • gene reduncdancy
    À¯ÀüÀÚ Áߺ¹(ë¶îîí­ñìÜÜ)
  • gene reiteration
    À¯ÀüÀÚ Áߺ¹(ë¶îîí­ñìÜÜ)
  • gene repetition
    À¯ÀüÀÚ ¹Ýº¹(ë¶îîí­ÚãÜÖ)
  • gene splicing
    À¯ÀüÀÚ(ë¶îîí­) ½ºÇöóÀ̽Ì
  • gene substitution
    À¯ÀüÀÚ Ä¡È¯(ë¶îîí­öÇüµ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CAP camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab...
CGA catabolite gene activator; color graphics adapter
CGP N-carbobenzoxy-glycyl-L-phenylalanine; chorionic growth hormone-prolactin; choline glycerophosphatid...
CGRP calcitonin gene-related peptide
cGRP calcitonin gene-related peptide
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CGRP-IR Calcitonin gene-related peptide-like immunoreactivity
CGRP Calcitonin gene-related polypeptide
CAP Catabolite gene activator protein
CAT Choramphenicol Acetyltransferase gene
CMGT Chromosome mediated gene transfer
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
statistical genetics The study of the applications of principles of statistics to problems in genetics.
(05 Mar 2000)
q in population genetics The frequency of the less common of two different alternative (allelic) versions of a gene. (the frequency of the more common allele is p).
(12 Dec 1998)
quantitative genetics The formal study of measurable genetic traits, traditionally but not necessarily confined to galtonian genetics.
(05 Mar 2000)
terminator regions (genetics) DNA sequences which signal the termination of transcription.
(12 Dec 1998)
trans-activation (genetics) Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.)
(12 Dec 1998)
translocation (genetics) A type of aberration characterised by fragmentation of a chromosome and transfer of the broken-off portion to another chromosome, often of a different pair.
(12 Dec 1998)
transplantation genetics Genetics as applied to the transplanting of tissues from one animal to another.
(05 Mar 2000)
epidemiological genetics The study of genetics as a phenomenon of defined populations by the criteria, methods, and objectives of epidemiology rather than of population genetics.
(05 Mar 2000)
allelic gene See: allele, dominance of traits.
(05 Mar 2000)
antibiotic resistance gene Genes in a microorganism which confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, or by being a mutant form of the antibiotic's target so that it can ignore it.
(09 Oct 1997)
autosomal gene A gene located on any chromosome other than the sex chromosomes (X or Y).
(05 Mar 2000)
bicoid gene A group of genes which are important to the proper development of the head and thorax in the embryo of the fruit fly Drosophila melanogaster.
(09 Oct 1997)
BRCA1 breast cancer susceptibility gene This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer.
(12 Dec 1998)
calcitonin gene-related peptide <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response.
It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene.
The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion.
Acronym: CGRP
(05 May 2002)
cancer susceptibility gene tumour suppressor gene
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á